← Eichor
Condition: Neoantigen Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neoantigen

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Phase 1 · 1 location(s) · Sichuan University · NCT06344156A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plu
Phase 1/Phase 2 · 1 location(s) · Yinghua Xu · NCT07495215A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
NA · 1 location(s) · Fudan University · NCT06682117Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07648069Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (
EARLY_Phase 1 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT05141474Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Phase 2 · 1 location(s) · National Cancer Centre, Singapore · NCT04912765Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Sub
Phase 1 · 1 location(s) · Sir Run Run Shaw Hospital · NCT06026800Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · Jinling Hospital, China · NCT06326736XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
NA · 1 location(s) · Wu Wenming · NCT06353646Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · Zhejiang University · NCT07123545KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Phase 1/Phase 2 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT07353645Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NA · 2 location(s) · The First Affiliated Hospital of Nanchang University · NCT06751966Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment
Phase 1 · 1 location(s) · Ruijin Hospital · NCT07067385To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With H
Phase 1 · 2 location(s) · Shenzhen Xinhe Biomedical · NCT07594964Personalized Neoantigen Peptide Vaccines for Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Seqker Biosciences, Inc. · NCT07002203Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NA · 2 location(s) · The First Affiliated Hospital of Nanchang University · NCT06751940Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06195293Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
EARLY_Phase 1 · 1 location(s) · Ruijin Hospital · NCT06577532A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung C
Phase 3 · 238 location(s) · Merck Sharp & Dohme LLC · NCT06623422Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treat
Phase 2 · 2 location(s) · The First Affiliated Hospital of Nanchang University · NCT06751901Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
Phase 2 · 2 location(s) · The First Affiliated Hospital of Nanchang University · NCT06751849Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
NA · 2 location(s) · The First Affiliated Hospital of Nanchang University · NCT06752057Personalized DC Vaccine for Postoperative Cancer
Phase 1 · 1 location(s) · Sichuan University · NCT04147078Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
EARLY_Phase 1 · 1 location(s) · Yongyi Zeng · NCT06406816Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Sichuan University · NCT06675201Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NA · 2 location(s) · The First Affiliated Hospital of Nanchang University · NCT06751953Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplas
Phase 1 · 1 location(s) · Sir Run Run Shaw Hospital · NCT06019702Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
NA · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06141369Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · Zhejiang University · NCT06995105Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · Ruijin Hospital · NCT06496373
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.